If you're below 27, expect the answer to be no but most providers will explain alternatives
Our findings suggest that a randomised controlled trial of GLP-1 receptor agonist use in people with diabetes and depression, anxiety, or both would be worthwhile. Professor Mark Taylor from Griffith University, and one of the studys authors, said: An earlier study examining Swedish registers found the use of GLP-1 medications to be associated with a reduced risk of alcohol use disorder
CarlssonLMPeltonenMAhlinSAnvedenBouchardCCarlssonBet alBariatric surgery and prevention of type 2 diabetes in Swedish obese subjects
D.LiJ.et al (2015)
Porter DW, Irwin N, Flatt PR, Hlscher C, Gault VA: Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice
Exenatide has demonstrated the ability to headache frequency [19], however its role in headache in raised ICP is yet to be fully determined headaches severity were similar in both trial arms [19]